BRIEF-Opus Genetics Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint For Phentolamine Ophthalmic Solution

Reuters
26 Jun
BRIEF-Opus Genetics Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint For Phentolamine Ophthalmic Solution

June 26 (Reuters) - Opus Genetics Inc IRD.O:

  • OPUS GENETICS ANNOUNCES VEGA-3 PHASE 3 TRIAL MET ITS PRIMARY ENDPOINT FOR PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% FOR THE TREATMENT OF PRESBYOPIA

  • OPUS GENETICS INC - VEGA-3 TRIAL MEETS KEY SECONDARY EFFICACY ENDPOINTS

  • OPUS GENETICS INC - TO FILE FDA APPLICATION IN SECOND HALF OF 2025

Source text: ID:nGNX9H4BBM

Further company coverage: IRD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10